SEARCH

SEARCH BY CITATION

References

  • 1
    Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709717.
  • 2
    Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:13091321.
  • 3
    Albert NM, Yancy CW, Liang L, et al. Use of aldosterone antagonists in heart failure. JAMA. 2009;21:16581665.
  • 4
    Weber K. Mechanisms of disease: aldosterone in congestive heart failure. N Engl J Med. 2001;345:16891697.
  • 5
    Brown N. Eplerenone: cardiovascular protection. Circulation. 2003;107:25122518.
  • 6
    Maron B, Leopold J. Aldosterone receptor antagonists: effective, but often forgotten. Circulation. 2010;121:934939.
  • 7
    Tang W, Parameswaran A, Maroo A, et al. Aldosterone receptor antagonists in the medical management of chronic heart failure. Mayo Clin Proc. 2005;80:16231630.
  • 8
    Borghi C, Boschi S, Ambrosioni E, et al. Evidence of a partial escape of rennin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. J Clin Pharmacol. 1993;33:4045.
  • 9
    Swedberg K, Eneroth , P, Kjekshus J, et al; CONSENSUS Trial Study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation. 1990;82:17301736.
  • 10
    Catena C, Colussi G, Nadalini E, et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008;168:8085.
  • 11
    Brilla CG. Aldosterone and myocardial fibrosis in heart failure. Herz. 2000;25:299306.
  • 12
    Cittadini A, Monti MG, Isgaard J, et al. Aldosterone receptor blockade improves left ventricular remodeling and increases ventricular fibrillation threshold in experimental heart failure. Cardiovasc Res. 2003;58:555564.
  • 13
    Schafer A, Fraccarollo D, Hildemann SK, et al. Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction. Cardiovasc Res. 2003;58:655662.
  • 14
    Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult-summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2005;46:1116.
  • 15
    Zannad F, McMurray JJV, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:1121.
  • 16
    Chan A, Sanderson J, Wang T, et al. Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure. J Am Coll Cardiol. 2007;50:591596.
  • 17
    Fletcher J, Buch A, Routledge H, et al. Acute aldosterone antagonism improves cardiac vagal control in humans. J Am Coll Cardiol. 2004;43:12701275.
  • 18
    Bernal J, Pitta SR, Thatai D. Role of the renin-angiotensin-aldosterone system in diastolic heart failure: potential for pharmacologic intervention. Am J Cardiovasc Drugs. 2006;6:373381.
  • 19
    Mottram PM, Haluska B, Leano R, et al. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation. 2004;110:558565.
  • 20
    Grandi AM, Imperiale D, Santillo R, et al. Aldosterone antagonist improves diastolic function in essential hypertension. Hypertension. 2002;40:647652.
  • 21
    Shah NC, Pringle SD, Donnan PT, et al. Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure. J Hypertens. 2007;25:23452351.
  • 22
    Yee KM, Pringle SD, Struthers AD. Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J Am Coll Cardiol. 2001;37:18001807.
  • 23
    Ouvrard-Pascaud A, Sainte-Marie Y, Benitah JP, et al. Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation. 2005;111:30253033.
  • 24
    Das MK, Zipes DP. Antiarrhythmic and nonantiarrhythmic drugs for sudden cardiac death prevention. J Cardiovasc Pharmacol. 2010;55:438449.
  • 25
    Pitt B, Pitt G. Added benefit of mineralocorticoid receptor blockade in the primary prevention of sudden cardiac death. Circulation. 2007;15:29762982.
  • 26
    Milliez P, DeAngelis N, Rucker-Martin C, et al. Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. Eur Heart J. 2005;26:21932199.
  • 27
    Shroff SC, Ryu K, Martovitz NL, et al. Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure. J Cardiovasc Electrophysiol. 2006;17:534541.
  • 28
    Nattel S. Aldosterone antagonism and atrial fibrillation: time for clinical assessment? Eur Heart J. 2005;26:20792080.
  • 29
    Makkar KM, Sanoski CA, Spinler SA. A role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias. Pharmacotherapy. 2006;29:3148.
  • 30
    Healey J, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol. 2005;45:18321839.
  • 31
    Schneider MP, Hua TA, Bohm M, et al. Prevention of atrial fibrillation by renin-angiotensin system inhibition: a meta-analysis. J Am Coll Cardiol. 2010;55:22992307.
  • 32
    Shah N, Pringle S, Struthers A. Aldosterone blockade over and above ACE-inhibitors in patients with coronary artery disease but without heart failure. J Renin Angiotensin Aldosterone Syst. 2006;71:2030.
  • 33
    Leopold JA, Dam A, Maron BA, et al. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med. 2007;13:189197.
  • 34
    Rajagopalan S, Damon D, King S, et al. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation. 2002;105:22122216.
  • 35
    Amano T, Matsubara T, Izawa H, et al. Impact of plasma aldosterone levels for prediction of in-stent restenosis. Am J Cardiol. 2006;97:785788.
  • 36
    Suzuki J, Iwai M, Mogi M, et al. Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. Arterioscler Thromb Vasc Biol. 2006;26:917921.
  • 37
    Keidar S, Hayek T, Kaplan M, et al. Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol. 2003;41:955963.
  • 38
    Beygui F, Collet JP, Benoliel JJ, et al. High plasma aldosterone levels on admission on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction. Circulation. 2006;114:25722574.
  • 39
    Beygui F, Vicaut E, Ecollan P, et al. Rationale for an early aldosterone blockade in acute myocardial infarction and design of the ALBATROSS trial. Am Heart J. 2010;160:642648.
  • 40
    Fujita T. Mineralocorticoid receptors, salt-sensitive hypertension, and metabolic syndrome. Hypertension. 2010;55:813818.
  • 41
    Sowers JR, Whaley-Connell A, Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med. 2009;150:776783.
  • 42
    Mitchell J, Ventura H, Meha M. Early recognition and treatment of hypertensive heart disease. Curr Opin Cardiol. 2005;20:282289.
  • 43
    Pitt B, Reichek N, Willenbrock R, et al. Effects of eplere- none, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-Left Ventricular Hypertrophy Study. Circulation. 2003;108: 18311838.